Chugai Pharmaceutical Files New Drug Application for Hemophilia A Treatment Emicizumab
Chugai Pharmaceutical filed a New Drug Application for the use of emicizumab as a potential treatment to prevent or decrease the occurrence of bleeding episodes in patients with hemophilia A with factor VIII inhibitors. The application is based on…